Penelitian Klinik Cleveland baru menunjukkan untuk pertama kalinya bahwa ibrutinib (ibrutinib) yang disetujui FDA untuk limfoma dan leukemia juga dapat membantu mengobati tumor otak yang paling umum dan mematikan, dan suatu hari nanti dapat digunakan pada pasien dengan glioblastoma dan meningkatkan tingkat kelangsungan hidup.
Menurut laporan American Brain Tumor Association, tingkat kelangsungan hidup glioblastoma sangat rendah, dan rata-rata kelangsungan hidup pasien yang menerima pengobatan standar kurang dari 15 bulan. Glioblastoma adalah tumor otak primer yang paling mematikan dan sangat resisten terhadap pengobatan saat ini. Ada kebutuhan mendesak untuk memberikan perawatan baru kepada pasien ini secepat mungkin.
In an earlier study, Bao and colleagues found that glioma stem cells contained high levels of a protein called BMX (bone marrow and X-linked non-receptor tyrosine kinase). BMX activates a protein called STAT3 (signal transduction and transcription activator 3), which is responsible for the invasive and tumorigenic properties of glioma stem cells. In this new study, the researchers found that ibrutinib works by inhibiting two proteins.
A research team led by Dr. Shideng Bao of the Cleveland Clinic Lerner Institute found that ibrutinib slowed the growth of brain tumor in a preclinical model and prolonged survival by more than 10 times that of existing standard chemotherapy drugs. Studies have found that ibrutinib works by inhibiting glioma stem cells, an aggressive brain cancer cell that tends to resist treatment and spread. In addition, combining ibrutinib with radiation therapy can prevent glioblastoma cells from developing drug resistance. Combination therapy is more effective than radiotherapy or ibrutinib alone in overcoming drug resistance and extending lifespan. Follow-up clinical trials are being carried out intensively, and we look forward to receiving FDA approval as soon as possible.
https://medicalxpress.com/news/2018-05-leukemia-lymphoma-drug-benefit-glioblastoma.html
